Cambrex

Activities: Ingredients

Trending Articles

  1. Sapio Sciences and ZS partner to digitise biopharma R&D and CMC laboratories The collaboration pairs Sapio's AI lab informatics platform with ZS's life sciences consulting expertise, delivering end-to-end ELN and LIMS deployment across regulated R&D and...
  2. T-CURX acquires Pantherna Therapeutics to fast-track non-viral in vivo CAR-T pipeline Combining transposon-based CAR-T with Pantherna's LNP and mRNA platforms, T-CURX aims to accelerate clinical trials by a year and become Europe's first biotech with both...
  3. Almac group delivers record year of growth Revenue rises to £1.1 billion as profit increases 16% and workforce expands to more than 7,900 amid continued global investment programme
  4. MasterControl strengthens executive leadership team with two key appointments ynn Clayton joins as CFO while Ian Ball is promoted to chief sales officer to support the company’s next phase of growth
  5. CellProthera appoints new board members for late-stage clinical development CellProthera, a clinical-stage biotechnology company developing regenerative cell therapies for ischemic diseases, today announced the appointment of Jérôme Hirtzlin and Anne...

Upcoming event

BIO International Convention

22–25 June 2026 | Convention | Boston, US See all

Related Content

Finance

Cambrex unveils $120m investment to expand API manufacturing and strengthen US drug supply resilience

Cambrex's continued investments underscore its commitment to adding capabilities and increasing capacity to meet the evolving needs and growing demand of the pharmaceutical industry.
Manufacturing

Cambrex optimises the peptide synthesis process with novel LPPS technology

The manufacturing solution reduces the reliance on specialised, solid-phase reactors, while being easily scalable and less resource-intensive
Distribution

Cambrex expands stability storage capabilities with novel US facility

The facility allows for pharmaceutical and medical device storage at a wide range of temperatures and humidity levels, serving the US market with next day delivery
Manufacturing

Cambrex completes expansion at small molecule API facility

The company has announced it has doubled the size of its small molecule active pharmaceutical ingredient (API) manufacturing facility
Manufacturing

Cambrex completes Snapdragon Chemistry acquisition

The company continues to expand its portfolio of specialised solutions for pharmaceutical development and manufacturing
Manufacturing

Cambrex set to acquire Snapdragon Chemistry

“The acquisition of Snapdragon will accelerate our growth in the area of continuous flow process development and manufacturing"
Manufacturing

Cambrex invests in 21,000 sqft R&D facility in Minnesota

The facility is located on a 45-acre property and produces a wide range of APIs and pharmaceutical intermediates, including highly potent molecules and controlled substances
Subscribe now